<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85565">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01771250</url>
  </required_header>
  <id_info>
    <org_study_id>14871</org_study_id>
    <secondary_id>I2R-MC-BIDN</secondary_id>
    <nct_id>NCT01771250</nct_id>
  </id_info>
  <brief_title>A Study of LY2605541 and Glargine on Fats in Participants With Type 1 Diabetes</brief_title>
  <official_title>Assessment of the Effects of LY2605541 on Triglyceride Metabolism, Compared to Insulin Glargine, in Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has two parts. Each participant will receive a daily injection of LY2605541
      during one treatment period and a daily injection of insulin glargine during the other
      treatment period. Each treatment period is 3 to 4 weeks and is followed by procedures to
      look at how the body uses or stores fats while taking each study drug.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentrations</measure>
    <time_frame>Day 22 of each treatment period from start of triglyceride metabolism assessment (TMA) procedure (time 0) up to 420 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>VLDL-TG Secretion Rate</measure>
    <time_frame>Day 22 of each treatment period from start of TMA procedure (time 0) up to 420 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>VLDL-TG Oxidation Rate</measure>
    <time_frame>Day 22 of each treatment period from start of TMA procedure (time 0) up to 420 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>VLDL-TG Clearance Rate</measure>
    <time_frame>Day 22 of each treatment period from start of TMA procedure (time 0) up to 420 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>LY2605541</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stable dose of LY2605541 (0.2 - 0.8 units per kilogram [U/kg]) administered subcutaneously (SQ) once daily for at least 21 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stable dose of insulin glargine (0.2 - 0.8 U/kg) administered SQ once daily for at least 21 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY2605541</intervention_name>
    <description>Daily doses administered SQ.</description>
    <arm_group_label>LY2605541</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Daily doses administered SQ.</description>
    <arm_group_label>Insulin Glargine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetic for more than 1 year with glycated hemoglobin (HbA1c) of less than
             8.5%

          -  Otherwise fit and healthy

          -  Non smoker

        Exclusion Criteria:

          -  Taking medication or supplements other than insulin to control diabetes.

          -  Suffered a hypoglycemic event in the last 12 months that required hospitalization or
             have poor awareness of hypoglycemia

          -  Taking fibrates, thyroid replacement therapy, testosterone, beta blockers or systemic
             corticosteroids
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>January 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glargine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
